FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended DECEMBER 31, 2022 Commission file number 0-10248 FONAR CORPORATION (Exact name of registrant as specified in its charter) | DELAWARE | | 11-2464137 | | --- | --- | --- | | (State or jurisdiction of | other | (I.R.S. Employer | | incorporation organization) | or | Identification No.) | | 110 Marcus Melville, New York | Drive | ...

FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended SEPTEMBER 30, 2022 Commission file number 0-10248 FONAR CORPORATION (Exact name of registrant as specified in its charter) | DELAWARE | 11-2464137 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 110 Marcus Drive Melville, New York | 11747 | | Ad ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 OR (Exact name of registrant as specified in its charter) DELAWARE 11-2464137 110 Marcus Drive, Melville, New York 11747 (Address of principal executive offices) (Zip Code) (State of incorporation) (IRS Employer Identification Number) (631) 694-2929 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI ...

FORM 10-Q SECURITIES AND EXCHANGE COMMISSION [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2022 Washington, D.C. 20549 Commission file number 0-10248 FONAR CORPORATION (Exact name of registrant as specified in its charter) | DELAWARE | 11-2464137 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | 110 Marcus Drive Melville, New York 11747 Address of pri ...

FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the quarterly period ended DECEMBER 31, 2021 Commission file number 0-10248 FONAR CORPORATION (Exact name of registrant as specified in its charter) | DELAWARE | | | | | 11-2464137 | | --- | --- | --- | --- | --- | --- | | (State or jurisdiction of | other | | | (I.R.S. | Employer | | incorporation or organization) | | | | Identification | No.) | | 110 ...

FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the quarterly period ended SEPTEMBER 30, 2021 Commission file number 0-10248 FONAR CORPORATION (Exact name of registrant as specified in its charter) | delaware | 11-2464137 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 110 Marcus Drive Melville, New York | 11747 | | Ad ...

FONAR CORPORATION (Exact name of registrant as specified in its charter) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File No. 0-10248 DELAWARE 11-2464137 (State of incorporation) (IRS Employ ...

FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2021 Commission file number 0-10248 | Class | Outstanding at May 5, 2021 | | --- | --- | | Common Stock, par value $.0001 | 6,554,210 | | Class B Common Stock, par value $.0001 | 146 | | Class C Common Stock, par value $.0001 | 382,513 | | Class A Preferred Stock, par value $.0001 | 313,438 | FONAR CORPORATION (Exac ...

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES _X_ NO ___ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of ...

Financial Performance - For the three-month period ended September 30, 2020, the company reported a net income of $3.3 million on revenues of $21.0 million, compared to a net income of $4.5 million on revenues of $21.7 million for the same period in 2019, indicating a revenue decrease of 3.2%[87][88] - Operating income decreased from $5.5 million for the three months ended September 30, 2019, to $4.2 million for the same period in 2020, reflecting a decline of 23.6%[89] - HMCA's revenues decreased by 2.4% to $19.0 million in the first three months of fiscal 2021 from $19.5 million in fiscal 2020[104] - Consolidated net revenues decreased by 3.5% to $21.0 million from $21.7 million for the first three months of fiscal 2020, while total costs and expenses increased by 3.5% to $16.8 million[112] - Selling, general and administrative expenses increased to $6.2 million in the first three months of fiscal 2021 from $4.3 million in the same period of fiscal 2020, an increase of 44.2%[113] - Research and development expenses decreased by 18% to $400,000 for the first three months of fiscal 2021 from $472,000 in the same period of fiscal 2020[114] - Foreign revenues decreased by 33.9% to approximately $121,000 in the first three months of fiscal 2021 from approximately $183,000 in fiscal 2020[100] Cash and Liabilities - The company reported a 5.3% increase in cash and cash equivalents, rising from $36.8 million at June 30, 2020 to $38.8 million at September 30, 2020[140] - Cash provided by operating activities for the first three months of fiscal 2021 was $3.8 million, primarily driven by net income of $3.3 million[141] - Total liabilities decreased by 1.5% to $53.2 million at September 30, 2020, down from $54.0 million at June 30, 2020[145] - Working capital increased to $80.5 million at September 30, 2020, up from $77.2 million at June 30, 2020, due to an increase in current assets[147] Technological Advancements - FONAR's Upright® MRI technology allows for scanning patients in multiple positions, significantly improving visualization of spinal abnormalities and treatment outcomes[124] - The Upright® MRI has shown a 250% increase in the visualization of cerebellar tonsil ectopia in patients scanned upright compared to lying down[131] - The UCLA study indicated that static single position MRI missed 35.1% of spondylolistheses and 23.75% of cervical disc bulges, emphasizing the importance of the Upright® MRI[136] - The company has developed a scanning protocol that allows scoliosis patients to obtain diagnostic images without the risks associated with x-rays, impacting over 3 million American women[132] Business Strategy and Future Outlook - The Company entered into a $701,000 loan agreement under the Paycheck Protection Program (PPP) to support Florida locations during COVID-19, with the expectation that most of the loan will be forgiven[155] - The Company has not committed to significant capital expenditures for the remainder of the 2021 fiscal year, except for placing additional scanners at 3 facilities in New York[156] - The business plan focuses on improving and expanding MRI facilities managed or owned by HMCA and increasing the number of scans performed[157] - Management aims to promote wider market recognition of Fonar's scanner products and increase demand for Upright® scanning despite market uncertainties[158] - The Company has achieved profitability for eight consecutive fiscal years and believes its capital resources will support operations through at least September 30, 2021[161] - The future effects of healthcare legislation, COVID-19, and economic conditions on the business are uncertain, but the Company has adequate revenues and cash reserves[161] - The Company maintains its funds in liquid accounts and does not invest in fixed rate instruments[162] - All revenue, expense, and capital purchasing activities are conducted in United States dollars[163]